Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
AnGes Inc
Athira Pharma Inc
AVEO Pharmaceuticals Inc
Beijing SH biotechnology Co Ltd
Helixmith Co Ltd
i2 Pharmaceuticals Inc
Kringle Pharma Inc
Minerva Biotechnologies Corp
Molecular Partners AG
PlateletBio
Yichang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
Ad-HGF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATH-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATH-1020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ficlatuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Liver Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to activate HGF for Lung Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
Featured News & Press Releases
Jul 06, 2021: Athira Pharma announces initiation of open label extension study for LIFT-AD and ACT-AD clinical trials of ATH-1017 for Alzheimer’s disease
Jun 07, 2021: AVEO Oncology to host key opinion leader webir on ficlatuzumab in head and neck squamous cell carcinoma
May 21, 2021: XOMA licensee AVEO to present significant clinical data on ficlatuzumab at 2021 ASCO Annual Meeting
May 19, 2021: AVEO Oncology announces positive results from randomized phase 2 study of ficlatuzumab in combition with cetuximab in pan-refractory, metastatic HNSCC
Apr 23, 2021: Helixmith announces poster presentations at the 2021 American Academy of Pain Medicine Meeting
Mar 10, 2021: Helixmith announces first patient enrolled in phase 2 study of Engensis (VM202) for Amyotrophic Lateral Sclerosis
Jan 22, 2021: Helixmith: Results from phase 3 gene therapy trial for diabetic peripheral neuropathy published online by Clinical and Translatiol Science
Dec 08, 2020: Athira Pharma awarded $15 million grant from tiol Institute on Aging to support ACT-AD clinical trial in Alzheimer’s Disease
Dec 01, 2020: Athira Pharma announces initiation of patient dosing for ACT-AD clinical trial of ATH-1017, small molecule HGF/MET activator, for treatment of mild-to-moderate Alzheimer’s disease
Nov 18, 2020: Helixmith announces first patient enrolled in phase 3 study of Engensis (VM202) for diabetic peripheral neuropathy
Oct 21, 2020: Athira Pharma to host educatiol webir on the predictive ture of P300 to determine clinical benefit of Alzheimer’s Disease treatments
Oct 01, 2020: Athira Pharma announces initiation of patient dosing for the LIFT-AD study, a Phase 2/3 clinical trial to evaluate ATH-1017 for treatment of mild-to-moderate Alzheimer’s Disease
Jul 27, 2020: Helixmith: VM202 CMT Phase I/IIA Trial Launched
Mar 27, 2020: AVEO Oncology and Biodesix to discontinue CyFi-2 study of Ficlatuzumab in Relapsed and Refractory AML in response to public health crisis
Feb 18, 2020: Helixmith provides update of gene therapy Phase 3 Trial for Painful Diabetic Peripheral Neuropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AnGes Inc, 2021
Pipeline by Athira Pharma Inc, 2021
Pipeline by AVEO Pharmaceuticals Inc, 2021
Pipeline by Beijing SH biotechnology Co Ltd, 2021
Pipeline by Helixmith Co Ltd, 2021
Pipeline by i2 Pharmaceuticals Inc, 2021
Pipeline by Kringle Pharma Inc, 2021
Pipeline by Minerva Biotechnologies Corp, 2021
Pipeline by Molecular Partners AG, 2021
Pipeline by PlateletBio, 2021
Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2021
Pipeline by Yooyoung Pharm Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Discontinued Products, 2021